Following a breast cancer diagnosis, it is uncertain whether women’s breast density knowledge influences their willingness to undergo pre-operative imaging to detect additional cancer in their ...
https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-024-01820-x
Breast cancer, the most prevalent cancer in women worldwide, faces treatment challenges due to drug resistance, posing a serious threat to patient survival. The present study aimed to identify th...
https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-024-01827-4
To compare the compartmentalized diffusion-weighted models, intravoxel incoherent motion (IVIM) and restriction spectrum imaging (RSI), in characterizing breast lesions and normal fibroglandular ...
https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-024-01828-3
Basal-like breast cancer (BLBC) is the most aggressive subtype of breast cancer due to its aggressive characteristics and lack of effective therapeutics. However, the mechanism underlying its agg...
https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-024-01825-6
We previously reported our phase Ib trial, testing the safety, tolerability, and efficacy of T-DM1 + neratinib in HER2-positive metastatic breast cancer patients. Patients with ERBB2 amplific...
https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-024-01823-8